Joel Becker is the President and Chief Executive Officer of NeuroPace Inc., a pioneering medical technology company dedicated to improving outcomes for patients with drug-resistant epilepsy through its RNS System, the first FDA-approved brain-responsive neurostimulation device. With more than 25 years of experience in the medical device industry, Becker brings deep expertise in neuromodulation, commercial strategy, and global market expansion. He assumed leadership at NeuroPace in September 2022, guiding the company through pivotal growth phases, including expanded reimbursement coverage, international market entry, and enhancements to the RNS platform that have enabled over 15,000 patient implants to date. Prior to NeuroPace, Becker served as Chief Commercial Officer at Nevro Corp., where he played a key role in scaling the company from a commercial-stage startup to a market leader in spinal cord stimulation for chronic pain, driving annual revenue growth exceeding 50% and securing Medicare coverage for innovative therapies. His earlier career includes senior leadership roles at Boston Scientific Corporation, where he led U.S. and international commercial operations for neuromodulation products, and at Advanced Bionics, contributing to the advancement of cochlear implant technologies. Becker's track record includes successfully launching multiple FDA-approved devices and building high-performing teams that have generated billions in revenue. Under Becker's stewardship, NeuroPace has accelerated clinical evidence generation, achieved record procedure growth, and strengthened its position as the only company offering responsive neurostimulation for epilepsy. His strategic focus on patient access, innovation, and operational excellence continues to propel NeuroPace toward broader adoption of personalized brain therapies.